Selection, design, and engineering of therapeutic antibodies
mAbs account for an increasing portion of marketed human biological therapeutics. As a consequence, the importance of optimal selection, design, and engineering of these not only has expanded in the past 2 decades but also is now coming into play as a competitive factor. This review delineates the 4...
Gespeichert in:
| Veröffentlicht in: | Journal of Allergy and Clinical Immunology 2005-10, Vol.116 (4), p.731-736 |
|---|---|
| 1. Verfasser: | |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 736 |
|---|---|
| container_issue | 4 |
| container_start_page | 731 |
| container_title | Journal of Allergy and Clinical Immunology |
| container_volume | 116 |
| creator | Presta, Leonard G. |
| description | mAbs account for an increasing portion of marketed human biological therapeutics. As a consequence, the importance of optimal selection, design, and engineering of these not only has expanded in the past 2 decades but also is now coming into play as a competitive factor. This review delineates the 4 basic areas for optimal therapeutic antibody selection and provides examples of the increasing number of considerations necessary for, and options available for, antibody design. Though some of the advances in antibody technology (eg, antibodies derived from phage-display libraries) have already made it to market, other more recent advances, such as engineering antibodies for enhanced effector functions, may not be far behind, especially given the increasing competition for therapeutic antibodies to the same target (eg, anti-CD20 and anti–TNF-α). |
| doi_str_mv | 10.1016/j.jaci.2005.08.003 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_68665937</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S009167490501715X</els_id><sourcerecordid>3238968351</sourcerecordid><originalsourceid>FETCH-LOGICAL-c509t-ecf3e25d55033cd3c7cb07ed69d35965e4ca6804d46d35026d71d752f227f4163</originalsourceid><addsrcrecordid>eNqFkU1r3DAQhkVJaTZp_kAOYSEkp9gdfduQSwj9gkAPbc5CK403Ml55I9mF_vtq2YVADslpkPTMy2geQs4p1BSo-tLXvXWhZgCyhqYG4B_IgkKrK9UweUQWAC2tlBbtMTnJuYdy5k37iRxTxSiA4Aty-xsHdFMY483SYw7rUm30S4zrEBFTiOvl2C2nJ0x2i_MUXHmewmr0AfNn8rGzQ8azQz0lj9--_rn_UT38-v7z_u6hchLaqULXcWTSSwmcO8-ddivQ6FXruWyVROGsakB4ocoFMOU19VqyjjHdCar4Kbne527T-DxjnswmZIfDYCOOczaqUUq2XL8LMhBSC7ZLvHwF9uOcYvmEoRJEYRopC8X2lEtjzgk7s01hY9M_Q8HsFJje7BSYnQIDjSkKStPFIXpebdC_tBx2XoCrA2Czs0OXbHQhv3CaQaMYK9ztnsOy2r8Bk8kuYHToQyrKjB_DW3P8By9_od0</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1504742855</pqid></control><display><type>article</type><title>Selection, design, and engineering of therapeutic antibodies</title><source>Wiley Online Library - AutoHoldings Journals</source><source>MEDLINE</source><source>IngentaConnect Free/Open Access Journals</source><source>Elsevier ScienceDirect Journals</source><source>Wiley Online Library Free Content</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>PubMed Central</source><creator>Presta, Leonard G.</creator><contributor>Shearer, WT ; Bochner, BS ; Rosenwasser, LJ</contributor><creatorcontrib>Presta, Leonard G. ; Shearer, WT ; Bochner, BS ; Rosenwasser, LJ</creatorcontrib><description>mAbs account for an increasing portion of marketed human biological therapeutics. As a consequence, the importance of optimal selection, design, and engineering of these not only has expanded in the past 2 decades but also is now coming into play as a competitive factor. This review delineates the 4 basic areas for optimal therapeutic antibody selection and provides examples of the increasing number of considerations necessary for, and options available for, antibody design. Though some of the advances in antibody technology (eg, antibodies derived from phage-display libraries) have already made it to market, other more recent advances, such as engineering antibodies for enhanced effector functions, may not be far behind, especially given the increasing competition for therapeutic antibodies to the same target (eg, anti-CD20 and anti–TNF-α).</description><identifier>ISSN: 0091-6749</identifier><identifier>EISSN: 1097-6825</identifier><identifier>EISSN: 1365-2567</identifier><identifier>DOI: 10.1016/j.jaci.2005.08.003</identifier><identifier>PMID: 16210043</identifier><identifier>CODEN: JACIBY</identifier><language>eng</language><publisher>New York, NY: Mosby, Inc</publisher><subject>Amino Acid Sequence ; Animals ; Antibodies, Monoclonal - chemistry ; Antibodies, Monoclonal - genetics ; Antibodies, Monoclonal - therapeutic use ; Antibody engineering ; Antibody-Dependent Cell Cytotoxicity ; biologic therapeutics ; Biological and medical sciences ; Colorectal cancer ; Competitive advantage ; Complementarity Determining Regions ; Drug Design ; Epidermal growth factor ; Epitopes ; Fundamental and applied biological sciences. Psychology ; Fundamental immunology ; Humans ; Immunoglobulin Fc Fragments - chemistry ; Immunoglobulin Fc Fragments - genetics ; Immunoglobulin Fc Fragments - therapeutic use ; Immunopathology ; Leukemia ; Ligands ; Lymphoma ; Medical sciences ; Mice ; Protein Engineering ; Proteins ; Rheumatoid arthritis ; Rodents ; target selection ; Vascular endothelial growth factor</subject><ispartof>Journal of Allergy and Clinical Immunology, 2005-10, Vol.116 (4), p.731-736</ispartof><rights>2005 American Academy of Allergy, Asthma and Immunology</rights><rights>2005 INIST-CNRS</rights><rights>Copyright Elsevier Limited Oct 2005</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c509t-ecf3e25d55033cd3c7cb07ed69d35965e4ca6804d46d35026d71d752f227f4163</citedby><cites>FETCH-LOGICAL-c509t-ecf3e25d55033cd3c7cb07ed69d35965e4ca6804d46d35026d71d752f227f4163</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.sciencedirect.com/science/article/pii/S009167490501715X$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,776,780,3537,27901,27902,65306</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=17208622$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/16210043$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><contributor>Shearer, WT</contributor><contributor>Bochner, BS</contributor><contributor>Rosenwasser, LJ</contributor><creatorcontrib>Presta, Leonard G.</creatorcontrib><title>Selection, design, and engineering of therapeutic antibodies</title><title>Journal of Allergy and Clinical Immunology</title><addtitle>J Allergy Clin Immunol</addtitle><description>mAbs account for an increasing portion of marketed human biological therapeutics. As a consequence, the importance of optimal selection, design, and engineering of these not only has expanded in the past 2 decades but also is now coming into play as a competitive factor. This review delineates the 4 basic areas for optimal therapeutic antibody selection and provides examples of the increasing number of considerations necessary for, and options available for, antibody design. Though some of the advances in antibody technology (eg, antibodies derived from phage-display libraries) have already made it to market, other more recent advances, such as engineering antibodies for enhanced effector functions, may not be far behind, especially given the increasing competition for therapeutic antibodies to the same target (eg, anti-CD20 and anti–TNF-α).</description><subject>Amino Acid Sequence</subject><subject>Animals</subject><subject>Antibodies, Monoclonal - chemistry</subject><subject>Antibodies, Monoclonal - genetics</subject><subject>Antibodies, Monoclonal - therapeutic use</subject><subject>Antibody engineering</subject><subject>Antibody-Dependent Cell Cytotoxicity</subject><subject>biologic therapeutics</subject><subject>Biological and medical sciences</subject><subject>Colorectal cancer</subject><subject>Competitive advantage</subject><subject>Complementarity Determining Regions</subject><subject>Drug Design</subject><subject>Epidermal growth factor</subject><subject>Epitopes</subject><subject>Fundamental and applied biological sciences. Psychology</subject><subject>Fundamental immunology</subject><subject>Humans</subject><subject>Immunoglobulin Fc Fragments - chemistry</subject><subject>Immunoglobulin Fc Fragments - genetics</subject><subject>Immunoglobulin Fc Fragments - therapeutic use</subject><subject>Immunopathology</subject><subject>Leukemia</subject><subject>Ligands</subject><subject>Lymphoma</subject><subject>Medical sciences</subject><subject>Mice</subject><subject>Protein Engineering</subject><subject>Proteins</subject><subject>Rheumatoid arthritis</subject><subject>Rodents</subject><subject>target selection</subject><subject>Vascular endothelial growth factor</subject><issn>0091-6749</issn><issn>1097-6825</issn><issn>1365-2567</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2005</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFkU1r3DAQhkVJaTZp_kAOYSEkp9gdfduQSwj9gkAPbc5CK403Ml55I9mF_vtq2YVADslpkPTMy2geQs4p1BSo-tLXvXWhZgCyhqYG4B_IgkKrK9UweUQWAC2tlBbtMTnJuYdy5k37iRxTxSiA4Aty-xsHdFMY483SYw7rUm30S4zrEBFTiOvl2C2nJ0x2i_MUXHmewmr0AfNn8rGzQ8azQz0lj9--_rn_UT38-v7z_u6hchLaqULXcWTSSwmcO8-ddivQ6FXruWyVROGsakB4ocoFMOU19VqyjjHdCar4Kbne527T-DxjnswmZIfDYCOOczaqUUq2XL8LMhBSC7ZLvHwF9uOcYvmEoRJEYRopC8X2lEtjzgk7s01hY9M_Q8HsFJje7BSYnQIDjSkKStPFIXpebdC_tBx2XoCrA2Czs0OXbHQhv3CaQaMYK9ztnsOy2r8Bk8kuYHToQyrKjB_DW3P8By9_od0</recordid><startdate>20051001</startdate><enddate>20051001</enddate><creator>Presta, Leonard G.</creator><general>Mosby, Inc</general><general>Elsevier</general><general>Elsevier Limited</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7SS</scope><scope>7T5</scope><scope>H94</scope><scope>K9.</scope><scope>NAPCQ</scope><scope>7X8</scope></search><sort><creationdate>20051001</creationdate><title>Selection, design, and engineering of therapeutic antibodies</title><author>Presta, Leonard G.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c509t-ecf3e25d55033cd3c7cb07ed69d35965e4ca6804d46d35026d71d752f227f4163</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2005</creationdate><topic>Amino Acid Sequence</topic><topic>Animals</topic><topic>Antibodies, Monoclonal - chemistry</topic><topic>Antibodies, Monoclonal - genetics</topic><topic>Antibodies, Monoclonal - therapeutic use</topic><topic>Antibody engineering</topic><topic>Antibody-Dependent Cell Cytotoxicity</topic><topic>biologic therapeutics</topic><topic>Biological and medical sciences</topic><topic>Colorectal cancer</topic><topic>Competitive advantage</topic><topic>Complementarity Determining Regions</topic><topic>Drug Design</topic><topic>Epidermal growth factor</topic><topic>Epitopes</topic><topic>Fundamental and applied biological sciences. Psychology</topic><topic>Fundamental immunology</topic><topic>Humans</topic><topic>Immunoglobulin Fc Fragments - chemistry</topic><topic>Immunoglobulin Fc Fragments - genetics</topic><topic>Immunoglobulin Fc Fragments - therapeutic use</topic><topic>Immunopathology</topic><topic>Leukemia</topic><topic>Ligands</topic><topic>Lymphoma</topic><topic>Medical sciences</topic><topic>Mice</topic><topic>Protein Engineering</topic><topic>Proteins</topic><topic>Rheumatoid arthritis</topic><topic>Rodents</topic><topic>target selection</topic><topic>Vascular endothelial growth factor</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Presta, Leonard G.</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Entomology Abstracts (Full archive)</collection><collection>Immunology Abstracts</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Premium</collection><collection>MEDLINE - Academic</collection><jtitle>Journal of Allergy and Clinical Immunology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Presta, Leonard G.</au><au>Shearer, WT</au><au>Bochner, BS</au><au>Rosenwasser, LJ</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Selection, design, and engineering of therapeutic antibodies</atitle><jtitle>Journal of Allergy and Clinical Immunology</jtitle><addtitle>J Allergy Clin Immunol</addtitle><date>2005-10-01</date><risdate>2005</risdate><volume>116</volume><issue>4</issue><spage>731</spage><epage>736</epage><pages>731-736</pages><issn>0091-6749</issn><eissn>1097-6825</eissn><eissn>1365-2567</eissn><coden>JACIBY</coden><abstract>mAbs account for an increasing portion of marketed human biological therapeutics. As a consequence, the importance of optimal selection, design, and engineering of these not only has expanded in the past 2 decades but also is now coming into play as a competitive factor. This review delineates the 4 basic areas for optimal therapeutic antibody selection and provides examples of the increasing number of considerations necessary for, and options available for, antibody design. Though some of the advances in antibody technology (eg, antibodies derived from phage-display libraries) have already made it to market, other more recent advances, such as engineering antibodies for enhanced effector functions, may not be far behind, especially given the increasing competition for therapeutic antibodies to the same target (eg, anti-CD20 and anti–TNF-α).</abstract><cop>New York, NY</cop><pub>Mosby, Inc</pub><pmid>16210043</pmid><doi>10.1016/j.jaci.2005.08.003</doi><tpages>6</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0091-6749 |
| ispartof | Journal of Allergy and Clinical Immunology, 2005-10, Vol.116 (4), p.731-736 |
| issn | 0091-6749 1097-6825 1365-2567 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_68665937 |
| source | Wiley Online Library - AutoHoldings Journals; MEDLINE; IngentaConnect Free/Open Access Journals; Elsevier ScienceDirect Journals; Wiley Online Library Free Content; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; PubMed Central |
| subjects | Amino Acid Sequence Animals Antibodies, Monoclonal - chemistry Antibodies, Monoclonal - genetics Antibodies, Monoclonal - therapeutic use Antibody engineering Antibody-Dependent Cell Cytotoxicity biologic therapeutics Biological and medical sciences Colorectal cancer Competitive advantage Complementarity Determining Regions Drug Design Epidermal growth factor Epitopes Fundamental and applied biological sciences. Psychology Fundamental immunology Humans Immunoglobulin Fc Fragments - chemistry Immunoglobulin Fc Fragments - genetics Immunoglobulin Fc Fragments - therapeutic use Immunopathology Leukemia Ligands Lymphoma Medical sciences Mice Protein Engineering Proteins Rheumatoid arthritis Rodents target selection Vascular endothelial growth factor |
| title | Selection, design, and engineering of therapeutic antibodies |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-04T00%3A08%3A45IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Selection,%20design,%20and%20engineering%20of%20therapeutic%20antibodies&rft.jtitle=Journal%20of%20Allergy%20and%20Clinical%20Immunology&rft.au=Presta,%20Leonard%20G.&rft.date=2005-10-01&rft.volume=116&rft.issue=4&rft.spage=731&rft.epage=736&rft.pages=731-736&rft.issn=0091-6749&rft.eissn=1097-6825&rft.coden=JACIBY&rft_id=info:doi/10.1016/j.jaci.2005.08.003&rft_dat=%3Cproquest_cross%3E3238968351%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1504742855&rft_id=info:pmid/16210043&rft_els_id=S009167490501715X&rfr_iscdi=true |